Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIα (p170) and IIβ (p180)

Molecular Pharmacology

Volumn 50, Issue 6, 1996, Pages 1463-1471

  Cornarotti, Mariagrazia ^a   Tinelli, Stella ^a   Willmore, Elaine ^b   Zunino, Franco ^a   Fisher, L Mark ^c   Austin, Caroline A ^b   Capranico, Giovanni ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 DEMETHOXYDOXORUBICIN; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DNA FRAGMENT; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIPODOPHYLLOTOXIN; RECOMBINANT ENZYME; TENIPOSIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHICKEN; DNA CLEAVAGE; DRUG SENSITIVITY; DRUG TARGETING; ENZYME SPECIFICITY; HUMAN; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; EPIRUBICIN; HUMANS; ISOENZYMES; MICE; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; TENIPOSIDE;

EID: 0030448769     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Wang, J. C. DNA topoisomerases. Anna. Rev. Biochem. 54:665-697 (1985).
2. Watt, P. M., and I. D. Hickson. Structure and function of type II DNA topoisomerases. Biochem. J. 303:681-695 (1994).
3. Pommier Y, and K. W. Kohn. Topoisomerase II inhibition by antitumor intercalators and demethylepipodophyllotoxins, in Developments in Cancer Chemotherapy (R. I. Glazer, ed.). CRC Press, Boca Raton, 175-195 (1989).
4. Capranico, G., and F. Zunino. DNA topoisomerase-trapping antitumour drugs. Eur. J. Cancer. 28A:2055-2060 (1992).
5. Capranico, G., K. W. Kohn, and Y. Pommier. Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res. 18:6611-6619 (1990).
6. Pommier, Y., G. Capranico, A. Orr, and K. W. Kohn. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. Nucleic Acids Res. 19:5973-5980 (1991) [published erratum appears in Nucleic Acids Res. 19:7003 (1991)].
7. Capranico, G., P. De Isabella, S. Tinelli, M. Bigioni, and F. Zunino. Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II. Biochemistry 32: 3038-3046 (1993).
8. Freudenreich, C. H., and K. N. Kreuzer. Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex. Proc. Natl. Acad. Sci. USA 91:11007-11011 (1994).
9. Drake, F. H., J. P. Zimmerman, F. L. McCabe, H. F. Bartus, S. R. Per, D. M. Sullivan, W. E. Ross, M. R. Mattern, R. K. Johnson, S. T. Crooke, C. K. Mirabelli. Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells: evidence for two forms of the enzyme. J. Biol. Chem. 262:16739-16747 (1987).
10. Austin, C. A., J.-H. Sng, S. Patel, and L. M. Fisher. Novel HeLa topoisomerase II is the IIb isoform: complete coding sequence and homology with other type II topoisomerases. Biochim. Biophys. Acta 1172:283-291 (1993).
11. Tsai-Pflugfelder, M., L. F. Liu, A. A. Liu, K. M. Tewey, J. Whang-Peng, T. Knutsen, K Huebner, C. M. Croce, and J. C. Wang. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc. Natl. Acad. Sci. USA 85:7177-7181 (1988).
12. Jenkins, J. R., P. Ayton, T. Jones, S. L. Davies, D. L. Simmons, A. L. Harris, D. Sheer, and I. D. Hickson Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res. 20:5587-5592 (1992).
13. Wasserman, R. A., C. A. Austin, L. M. Fisher, and J. C. Wang. Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombinant human DNA topoisomerase IIa in yeast. Cancer Res. 53:3591-3596 (1993).
14. Austin, C. A., K. L. Marsh, R. A. Wasserman, E. Willmore, P. J. Sayer, J. C. Wang, and L. M. Fisher. Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase IIb. J. Biol. Chem. 270:15739-15746 (1995).
15. Woessner, R. D., T. D. Chung, G. A. Hofmann, M. R. Mattern, C. K. Mirabelli, F. H. Drake, and R. K. Johnson. Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170 kD and 180 kD forms of topoisomerase II. Cancer Res. 50:2901-2908 (1990).
16. Woessner, R. D., M. R. Mattern, C. K. Mirabelli, R. K. Johnson, and F. H. Drake. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 2:209-214 (1991).
17. Capranico, G., S. Tinelli, C. A. Austin, M. L. Fisher, and F. Zunino. Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim. Biophys. Acta 1132:43-48 (1992).
18. Tsutsui, K., S. Okada, M. Watanabe, T. Shohmori, S. Seki, and Y. Inoue. Molecular cloning of partial cDNAs for rat DNA topoisomerase II isoforms and their differential expression in brain development. J. Biol. Chem. 268:19076-19083 (1993).
19. Burden, D. A., and D. M. Sullivan. Phosphorylation of the alpha- and beta-isoforms of DNA topoisomerase II is qualitatively different in interphase and mitosis in Chinese hamster ovary cells. Biochemistry 33:14651-14655 (1994).
20. Drake, F. H., G. A. Hofmann, H. F. Bartus, M. R. Mattern, S. T. Crooke, and C. K. Mirabelli. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 28:8154-8160 (1989).
21. Capranico, G., R. Supino, M. Binaschi, L. Capolongo, M. Grandi, A. Suarato, and F. Zunino. Influence of structural modifications at the 3′ and 4′ positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance. Mol. Pharmacol. 45:908-915 (1994).
22. Worland, S. T., and J. C. Wang. Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae. J. Biol. Chem. 264:4412-4416 (1989).
23. De Isabella, P., G. Capranico, M. Binaschi, S. Tinelli, and F. Zunino. Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells. Mol. Pharmacol. 37:11-16 (1990).
24. Bigioni, M., F. Zunino, and G. Capranico. Base mutational analysis of topoisomerase II-idarubicin-DNA ternary complex formation: evidence for enzyme subunit cooperativity in DNA cleavage. Nucleic Acids Res. 22: 2274-2281 (1994).
25. Roca, J., and J. C. Wang. The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases. Cell 71:833-840 (1992).
26. Berger, J. M., S. J. Gamblin, S. C. Harrison, and J. C. Wang. Structure and mechanism of DNA topoisomerase II. Nature (Lond.) 379:225-232 (1996).
27. Sander, M., and T. Hsieh. Double strand DNA cleavage by type II DNA topoisomerase from Drosophila melanogaster. J. Biol. Chem. 258:8421-8428 (1983).
28. Fisher, L. M., H. A. Barot, and M. E. Cullen. DNA gyrase complex with DNA: determinants for site-specific DNA breakage. EMBO J. 5:1411-1418 (1986).
29. Spitzner, J. R., and M. T. Muller. A consensus sequence for cleavage by vertebrate DNA topoisomerase II. Nucleic Acids Res. 16:5533-5556 (1988).
30. Spitzner, J. R., I. K. Chung, T. D. Gootz, P. R. McGuirk, and M. T. Muller. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements. Mol. Pharmacol. 48:238-249 (1995).
31. Huff, A. C., R. G. Robinson, A. C. Evans, K. N. Selander, M. P. Wentland, J. B. Rake, and S. A. Coughlin. DNA sequence preferences at sites cleaved by human DNA topoisomerase II in response to novel quinolone derivatives. Anti-Cancer Drug Des. 10:251-276 (1995).
32. Nitiss, J. L., Y. X. Liu, P. Harbury, M. Jannatipour, R. Wasserman, and J. C. Wang. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res. 52:4467-4472 (1992).
33. Pommier, Y. DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother. Pharmacol. 32:103-108 (1993).
34. r 160,000 topoisomerase IIα is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line. Cancer Res. 55:2129-2134 (1995).
35. Harker, W. G., D. L. Slade, F. H. Drake, and R. L. Parr. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 30:9953-9961 (1991).
36. Markovits, J., S. Junqua, F. Goldwasser, A. Venuat, C. Luccioni, J. Beaumatin, J. Saucier, A. Bernheim, and A. Jacquemin-Sablon. Genistein resistance in human leukaemic CCRF-CEM cells: selection of a diploid cell line with reduced DNA topoisomerase II beta isoform. Biochem. Pharmacol. 50:177-186 (1995).
37. Harker, W. G., D. L. Slade, R. L. Parr, and M. H. Holguin. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone. Cancer Res. 55:4962-4971 (1995).
38. Houlbrook, S., C. M. Addison, S. L. Davies, J. Carmichael, I. J. Stratford, A. L. Harris, and I. D. Hickson. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br. J. Cancer 72:1454-1461 (1995).
39. Zini, N., S. Santi, A. Ognibene, A. Bavelloni, L. M. Neri, A. Valmori, E. Mariani, C. Negri, G. C. Astaldi-Ricotti, and N. M. Maraldi. Discrete localization of different DNA topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions. Exp. Cell Res. 210:336-348 (1994).